Neurodegenerative Diseases: Genes, Mechanisms and Therapeutics

Web Desc
Neurodegenerative Diseases: Genes, Mechanisms and Therapeutics
joint with NeuroImmune Interactions in Health and Disease
Scientific Organizers: Eric J. Huang, Alison Goate and Richard M. Ransohoff
Date: June 05 - 09, 2021
Location: Keystone Resort, Keystone, CO, USA
Supported by the Directors' Fund
For important information on the coronavirus, please click here
Summary of Meeting:
The global burden of neurodegenerative diseases is staggering and growing at an alarming rate as the population ages. While it is well-recognized that neurodegenerative diseases are characterized by aberrant protein misfolding and aggregate formation, the mechanisms that initiate or promote proteinopathy in disease-specific neural circuits remain poorly understood. Recent advances in human genetics and genome-wide association study (GWAS) have uncovered several genetic loci that are critical for the pathogenesis of neurodegenerative diseases. Furthermore, technological advances in transcriptomics, proteomics, and metabolomics offer many critical new insights into the disease mechanism, as well as opportunities for the development of novel therapeutics that can reverse or mitigate neurodegeneration. Despite these exciting new developments, there are significant gaps in connecting genetic information with disease mechanism and in harnessing the critical role of glia-neuron interactions to develop therapeutic interventions. This conference aims to provide an integrated discussion of the latest advances in research and therapeutic development for neurodegenerative diseases. Our goals are to focus on the roles of genetic risk factors and their contributions to glial and neuronal health in the aging brain, the biophysical properties of protein misfolding and the propagation of disease-specific proteinopathy, the role of intracellular vesicular trafficking in disease pathogenesis, new insights into the diverse role of glia, innate immunity and microbiomes in neurodegeneration, and novel therapeutic approaches that specifically target each of the novel biological areas. We anticipate that this conference will stimulate more discussions and promote new collaborations among scientists in the academia and industry that ultimately lead to new therapeutic targets to combat neurodegenerative diseases.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: February 17 2021 details
Abstract Deadline: March 9 2021 details & pricing
Discounted Registration Deadline: April 6 2021 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found